MedTrace Logo

Study on B-blockers to Prevent Decompensation of Cirrhosis With HTPortal

NCT01059396 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 201

Last updated 2017-08-22

No results posted yet for this study

Summary

This is a multicenter, randomized, double-blind, placebo-controlled study on the effectiveness of treatment with beta-blockers to prevent decompensation of cirrhosis with portal hypertension.

Conditions

  • Portal Hypertension Gastropathy
  • Esophageal Varices
  • Spontaneous Bacterial Peritonitis
  • Hepatic Encephalopathy
  • Ascites

Interventions

DRUG

propranolol

GPVH ≥ 10 mmHg - responders: propranolol.

DRUG

carvedilol

GPVH ≥ 10 mmHg nonresponders: carvedilol.

DRUG

placebo

placebo propranolol / carvedilol

Sponsors & Collaborators

  • Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

    lead OTHER

Principal Investigators

  • Càndid Villanueva Sánchez, MD · Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-01-28
Primary Completion
2015-07-15
Completion
2015-07-15

Countries

  • Spain

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01059396 on ClinicalTrials.gov